Cargando…

Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery

Glioblastoma multiforme (GBM) is an aggressive brain tumor with high mortality rates. Due to its invasiveness, heterogeneity, and incomplete resection, the treatment is very challenging. Targeted therapies such as tyrosine kinase inhibitors (TKIs) have great potential for GBM treatment, however, the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brar, Harpinder K., Jose, Jiney, Wu, Zimei, Sharma, Manisha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863099/ https://www.ncbi.nlm.nih.gov/pubmed/36678688 http://dx.doi.org/10.3390/pharmaceutics15010059

Ejemplares similares

A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme
por: Nehoff, Hayley, et al.
Publicado: (2015)

Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme
por: Tilak, Manali, et al.
Publicado: (2021)

New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme
por: Singh, Manisha, et al.
Publicado: (2022)

Current Perspective on the Natural Compounds and Drug Delivery Techniques in Glioblastoma Multiforme
por: Behl, Tapan, et al.
Publicado: (2021)

Drug Delivery Nanosystems for the Localized Treatment of Glioblastoma Multiforme
por: Nam, L., et al.
Publicado: (2018)

Biomimetic nanotherapeutics for targeted drug delivery to glioblastoma multiforme
por: Lim, Xin Yuan, et al.
Publicado: (2023)

Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors
por: Yuan, Jie, et al.
Publicado: (2018)

Intersections of Ubiquitin-Proteosome System and Autophagy in Promoting Growth of Glioblastoma Multiforme: Challenges and Opportunities
por: Visintin, Rhett, et al.
Publicado: (2022)

Reassessing the Role of Intra-Arterial Drug Delivery for Glioblastoma Multiforme Treatment
por: Ellis, Jason A., et al.
Publicado: (2015)

Drug Delivery Nanosystems in Glioblastoma Multiforme Treatment: Current State of the Art
por: Di Filippo, Leonardo Delello, et al.
Publicado: (2021)

Retraction Note: Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors
por: Yuan, Jie, et al.
Publicado: (2021)

Evaluation of Tyrosine Kinase Inhibitor Combinations for Glioblastoma Therapy
por: Joshi, Avadhut D., et al.
Publicado: (2012)

Drug repurposing for the treatment of glioblastoma multiforme
por: Abbruzzese, Claudia, et al.
Publicado: (2017)

Drug target ranking for glioblastoma multiforme
por: Saraf, Radhika, et al.
Publicado: (2021)

Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment
por: Jackson, Christopher, et al.
Publicado: (2011)

Poly(ethylene glycol) based nanotubes for tuneable drug delivery to glioblastoma multiforme
por: Alghamdi, Majed, et al.
Publicado: (2020)

Revisiting CDK Inhibitors for Treatment of Glioblastoma Multiforme
por: Lubanska, Dorota, et al.
Publicado: (2017)

Glioblastoma Multiforme
por: Sheehan, Jonas M., et al.
Publicado: (2012)

Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
por: Aldaz, Paula, et al.
Publicado: (2021)

Nanotechnology and Nanocarrier-Based Drug Delivery as the Potential Therapeutic Strategy for Glioblastoma Multiforme: An Update
por: Hsu, Jen-Fu, et al.
Publicado: (2021)

Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4-d]pyrimidines as Dual Tyrosine Kinase Inhibitors Active against Glioblastoma Multiforme
por: Poggialini, Federica, et al.
Publicado: (2023)

Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Smart Drug Delivery Systems in the Treatment of Glioblastoma Multiforme
por: Jnaidi, Raneem, et al.
Publicado: (2020)

Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme
por: Jena, Lynn, et al.
Publicado: (2019)

Increased EGFRvIII Epitope Accessibility after Tyrosine Kinase Inhibitor Treatment of Glioblastoma Cells Creates More Opportunities for Immunotherapy
por: Tręda, Cezary, et al.
Publicado: (2023)

Glioblastoma multiforme – an overview
por: Urbańska, Kaja, et al.
Publicado: (2014)

Incidentalomas to glioblastoma multiforme
por: Sachdev, Bobby, et al.
Publicado: (2014)

Significant Effect of Anti-tyrosine Kinase Inhibitor (Gefitinib) on Overall Survival of the Glioblastoma Multiforme Patients in the Backdrop of Mutational Status of Epidermal Growth Factor Receptor and PTEN Genes
por: Arif, Sajad Hussain, et al.
Publicado: (2018)

Glioblastoma multiforme: A bigger challenge in resource-limited countries
por: Aung, LeLe
Publicado: (2013)

Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474)
por: LIN, LEHANG, et al.
Publicado: (2013)

Genetic variations in AURORA cell cycle kinases are associated with glioblastoma multiforme
por: Mesic, Aner, et al.
Publicado: (2021)

In silico studies on marine actinomycetes as potential inhibitors for Glioblastoma multiforme
por: Kirubakaran, Palani, et al.
Publicado: (2011)

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
por: Xavier, Mary-Ann, et al.
Publicado: (2021)

SYST-31 PROBIOTIC DELIVERY TO ORTHOTOPIC GLIOBLASTOMA MULTIFORME MODELS AS AN IMMUNOTHERAPY
por: Windemuth, Sophia, et al.
Publicado: (2023)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma
por: Bolcaen, Julie, et al.
Publicado: (2021)

The kinase inhibitor SI113 induces autophagy and synergizes with quinacrine in hindering the growth of human glioblastoma multiforme cells
por: Matteoni, Silvia, et al.
Publicado: (2019)

Drug delivery, biodistribution and anti-EGFR activity: theragnostic nanoparticles for simultaneous in vivo delivery of tyrosine kinase inhibitors and kinase activity biosensors
por: Bofinger, Robin, et al.
Publicado: (2021)

Metabolism-related pharmacokinetic drug−drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations
por: Teo, Yi Ling, et al.
Publicado: (2015)

Tectal plate glioblastoma multiforme
por: Nemer, Michael D., et al.
Publicado: (2011)

Bilateral cystic glioblastoma multiforme
por: Kumar, Sushil, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_b65m84ojmnhgg5v62v3jj9h960